|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||7.86 - 7.86|
|52 Week Range||3.22 - 10.00|
|Beta (5Y Monthly)||2.21|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Provention Bio, Inc. ( NASDAQ:PRVB ) is possibly approaching a major achievement in its business, so we would like to...
A look at the shareholders of Provention Bio, Inc. ( NASDAQ:PRVB ) can tell us which group is most powerful. The group...
Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.